Jazz Pharmaceuticals (JAZZ) and partner PharmaMar have announced a surprise early approval from the US FDA for its Zepzelca treatment for adults with …
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that the first patient has been enrolled in a Phase 3 clinical trial comparing the efficacy and safety …
Analyst Irina Koffler from Mizuho Securities reiterated her Buy rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with a raised price target of $195, marking …
Celator Pharmaceuticals Inc (NASDAQ:CPXX) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that they have entered into a definitive agreement for Jazz Pharmaceuticals to acquire Celator …